A population‐based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer

• DOI: 10.1002/cncr.24051
• Publication Date: 2009-01-08T19:38:30Z
• Authors: Daniel Y. C. Heng; Kim N Chi; Nevin Murray; Tao Jin; Jorge A Garcia; Ronald M Bukowski; Brian I Rini; Christian Kollman...
• Keywords: Kidney cancer

Abstract BACKGROUND: Sunitinib has replaced interferon (IFN) as a first‐line standard of care in the treatment metastatic renal cell carcinoma (RCC). This study aimed to determine overall survival and confirm effectiveness population that includes poor prognosis patients. METHODS: Data were collected on all patients identified by BC Cancer Registry with RCC who treated IFN or sunitinib. The group consisted received between January 2000 October 2005, sunitinib included from 2005 September 2007. RESULTS: There 131 69 groups, respectively. median follow‐up those still alive was 12.6 months. age (62 vs 63 years; P = .41), Memorial Sloan Kettering Center (MSKCC) prognostic criteria (poor 19% 30%; proportion >1 metastasis (53% 62%; .21) similar groups 8.7 17.3 months, respectively (log‐rank .004). favorable, intermediate, MSKCC profiles 22.9, 8.7, 4.1 ( < .001), whereas it not reached, 16.8, 10.7 .006). hazard ratio death after adjusting for 0.49 (95% confidence interval, 0.31‐0.76; .001). CONCLUSIONS: introduction associated doubling compared alone. benefit extended profiles. 2009. © 2009 American Society.